While pharma companies are increasingly licensing assets from Chinese biotechs, they are not acquiring them. This dichotomy highlights how geopolitical tensions and logistical complexities are creating a ceiling on US-China biotech integration, limiting partnerships to licensing-in rather than full M&A.
Even while its antisense drug Pella Carson was in a major Phase 3 trial, Novartis proactively licensed a competing siRNA technology for the same target. This suggests a sophisticated hedging strategy or internal doubts about the original drug's prospects, a move made years before the trial's failure.
Pharma's deal-making in the past year shows a renewed appetite for risk. Unlike the previous focus on validated targets during the bear market, companies are now investing heavily in disruptive, less-proven technologies like T-cell engagers for autoimmune disease, signaling a strategic pivot toward high-reward innovation.
Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.
The failure of Novartis's antisense drug Pella Carson, contrasted with the potential success of Amgen's siRNA targeting the same pathway, could have a profound negative impact on the entire antisense field, favoring siRNA technology for large population diseases.
The White House's Most Favored Nation (MFN) drug pricing deals are not as sweeping as portrayed. Companies are successfully negotiating significant carve-outs, such as forward-looking exclusions for all orphan drugs, which may render the agreements less impactful than the administration claims.